HUP0301621A3 - Use of integrin inhibitor for inhibiting angiogenesis and tumor growth - Google Patents

Use of integrin inhibitor for inhibiting angiogenesis and tumor growth

Info

Publication number
HUP0301621A3
HUP0301621A3 HU0301621A HUP0301621A HUP0301621A3 HU P0301621 A3 HUP0301621 A3 HU P0301621A3 HU 0301621 A HU0301621 A HU 0301621A HU P0301621 A HUP0301621 A HU P0301621A HU P0301621 A3 HUP0301621 A3 HU P0301621A3
Authority
HU
Hungary
Prior art keywords
tumor growth
inhibiting angiogenesis
integrin inhibitor
integrin
inhibitor
Prior art date
Application number
HU0301621A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of HUP0301621A2 publication Critical patent/HUP0301621A2/hu
Publication of HUP0301621A3 publication Critical patent/HUP0301621A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
HU0301621A 2000-03-27 2001-03-27 Use of integrin inhibitor for inhibiting angiogenesis and tumor growth HUP0301621A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19226000P 2000-03-27 2000-03-27
PCT/US2001/009785 WO2001072297A1 (en) 2000-03-27 2001-03-27 Methods for inhibiting angiogenesis and tumor growth

Publications (2)

Publication Number Publication Date
HUP0301621A2 HUP0301621A2 (hu) 2003-09-29
HUP0301621A3 true HUP0301621A3 (en) 2009-06-29

Family

ID=22708924

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0301621A HUP0301621A3 (en) 2000-03-27 2001-03-27 Use of integrin inhibitor for inhibiting angiogenesis and tumor growth
HU0301797A HUP0301797A3 (en) 2000-03-27 2001-03-27 Inhibition of angiogenesis and tumor growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0301797A HUP0301797A3 (en) 2000-03-27 2001-03-27 Inhibition of angiogenesis and tumor growth

Country Status (15)

Country Link
EP (2) EP1272173A4 (ru)
JP (2) JP2003528850A (ru)
KR (2) KR100767616B1 (ru)
CN (2) CN1229339C (ru)
AU (4) AU5101801A (ru)
CA (3) CA2659030A1 (ru)
CZ (2) CZ20023510A3 (ru)
HU (2) HUP0301621A3 (ru)
MX (2) MXPA02009510A (ru)
NO (2) NO328969B1 (ru)
PL (2) PL358272A1 (ru)
RU (2) RU2276133C2 (ru)
SK (2) SK14852002A3 (ru)
WO (2) WO2001072699A1 (ru)
ZA (2) ZA200208628B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2315721T5 (es) 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
UA97286C2 (ru) 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
KR20000068415A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법
EP0968423A4 (en) * 1997-02-07 2002-10-30 Scripps Research Inst CONVERGENT SYNTHESIS OF COMBINATORIAL BANKING
KR100596109B1 (ko) * 1998-03-27 2006-07-05 제넨테크, 인크. Ｃｄ11/ｃｄ18 부착 수용체 매개 질환 치료용 길항제

Also Published As

Publication number Publication date
CA2403630C (en) 2009-05-26
JP2003528850A (ja) 2003-09-30
RU2276133C2 (ru) 2006-05-10
CA2659030A1 (en) 2001-10-04
EP1272173A4 (en) 2006-05-03
CN1245967C (zh) 2006-03-22
EP1272173A1 (en) 2003-01-08
AU2001251018B2 (en) 2005-12-01
WO2001072699A1 (en) 2001-10-04
MXPA02009504A (es) 2003-05-21
AU4949901A (en) 2001-10-08
CZ20023510A3 (cs) 2003-03-12
KR20020091156A (ko) 2002-12-05
KR20020084258A (ko) 2002-11-04
AU2001249499B2 (en) 2005-04-21
CA2403630A1 (en) 2001-10-04
AU5101801A (en) 2001-10-08
NO20024578L (no) 2002-11-20
CZ20023509A3 (cs) 2003-06-18
SK14852002A3 (sk) 2003-06-03
CA2403871C (en) 2010-05-11
HUP0301797A3 (en) 2010-09-28
ZA200208626B (en) 2004-02-16
NO20024576L (no) 2002-11-20
CA2403871A1 (en) 2001-10-04
CN1229339C (zh) 2005-11-30
PL358272A1 (en) 2004-08-09
RU2269339C2 (ru) 2006-02-10
CN1429106A (zh) 2003-07-09
CN1441777A (zh) 2003-09-10
PL366316A1 (en) 2005-01-24
KR100767616B1 (ko) 2007-10-18
NO328969B1 (no) 2010-06-28
SK14842002A3 (sk) 2003-04-01
KR100776185B1 (ko) 2007-11-16
JP2003528140A (ja) 2003-09-24
HUP0301621A2 (hu) 2003-09-29
NO20024576D0 (no) 2002-09-24
NO20024578D0 (no) 2002-09-24
WO2001072297A1 (en) 2001-10-04
EP1276713A1 (en) 2003-01-22
RU2002128751A (ru) 2004-03-10
HUP0301797A2 (hu) 2003-09-29
EP1276713A4 (en) 2006-05-03
PL205134B1 (pl) 2010-03-31
ZA200208628B (en) 2004-02-12
MXPA02009510A (es) 2003-05-21

Similar Documents

Publication Publication Date Title
EP1097165A4 (en) NEW INHIBITORS OF ANGIOGENESIS AND TUMOR GROWTH
GB0025782D0 (en) Use of inhibitors
HK1053124A1 (en) Substituted quinazoline derivatives and their use as inhibitors
HUP0302693A3 (en) Phenylalanin-derivatives, integrin inhibitors of alpha4, their use and process for their preparation
IL145346A0 (en) Dimeric compounds and their use as inhibitors of neuraminidase
HK1043113A1 (zh) 端粒酶抑制劑及其使用方法
AU2026302A (en) Shale hydration inhibition agent and method of use
IL155122A0 (en) New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
AU8969601A (en) New use of lipase inhibitors
PL366338A1 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
ZA200106197B (en) Use of glycogen phosphorlase inhibitors to inhibit tumor growth.
PL356427A1 (en) Indol-3-yl derivatives and their use as integrin inhibitors
HK1052877A1 (zh) Ssri與雌激素劑之組合
AU8235601A (en) Dispenser and method of use
IL152792A0 (en) Heterocycle derivatives and methods of use
PL359668A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
HUP0301621A3 (en) Use of integrin inhibitor for inhibiting angiogenesis and tumor growth
HRP20020970A2 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
HK1053825B (zh) 酰胼和烷氧基酰胺血管發生抑制劑
HUP0201729A3 (en) Inhibitors of the integrin alpha v betha 6
IL154927A0 (en) Combination of statins and sorbitol dehydrogenase inhibitors
AU4587901A (en) Bisubstrate inhibitors of kinases
AU1212002A (en) Use of lipase inhibitors
IL162760A0 (en) Polyphenol inhibition of nucleosidediphosphate kinase-b activity and cancer

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees